Swiss biopharma firm Idorsia discusses convertible bond repayment ahead of bondholder meeting.

Idorsia Ltd, a Swiss biopharma firm, has published its unaudited financials for Mar 31, 2024, ahead of a bondholder meeting rescheduled to early May. The company is discussing convertible bond repayment due July 17, 2024. Idorsia, with over 750 specialists, aims to become a leading biopharma firm with innovative medicines for patients. The upcoming bondholder meeting will address proposed amendments to the bond's terms.

April 17, 2024
5 Articles

Further Reading